Post-Stem Cell Transplant Chimerism Monitoring

TRIAL NO: 242501 **Participant:** **ISSUED:** 9-May-24 **CLOSING:** 7-Jun-24

SAMPLE INFORMATION

Please find enclosed four 1mL peripheral blood samples (date samples taken 07 May 2024) for post-transplant chimerism analysis.

Sample ID (approximate total white cell count):

- **Donor 333** (6.6 x10^6)
- **Recipient 334** (6.6 x10^6)
- **Post-SCT 335** (6.6 x10^6)
- **Post-SCT 336** (6.6 x10^6)

IMPORTANT: Please perform your assay on the whole blood sample as opposed to separate cell lineages.

The molecular haemato-oncology programmes provided by UK NEQAS LI are open to any appropriate DNA/RNA based approaches; UK NEQAS LI does not endorse any particular testing methodology. **Wherever possible, please ensure that you treat the samples as routine specimens, adhering to standard operating procedures and local quality control (QC).** Details of methodologies used should be included in your results submission. Please note that results from all methods are performance monitored collectively, and not by individual methodological approaches, however, results may be considered by method in tables and figures for information only. There are no specific environmental conditions that need to be considered during testing of this External Quality Assessment (EQA) material.

SAMPLE STABILITY, STORAGE AND PROCESSING

The fresh peripheral blood sample(s) issued with this trial should be considered to have the same stability as routine diagnostic samples; **participants are advised to proceed with nucleic acid extraction upon receipt. If storage of the samples is necessary it should be at 2-8°C.**

Using the above cell count, determine the appropriate volume of sample needed for your laboratory protocol. Take care to ensure that all cells are thoroughly homogenised in your chosen lysate/re-suspension buffer. If applicable to your extraction methodology a red blood cell lysis step should be performed on these samples.

The DNA/RNA extracted should be subjected to local quality control procedures (e.g. spectrophotometry). **If the extracted nucleic acid does not meet local quality control procedures a repeat sample should be requested as soon as possible** (see the section below for guidance on requesting a repeat sample).

Materials used in the production of samples for UK NEQAS LI EQA programmes are obtained from a variety of sources. In all cases these materials (patient samples, cell lines, blood products etc) are provided under the conditions that they be used only for the educational purpose of EQA. **Participants must only use the samples provided for the purpose intended**. UK NEQAS LI, Sheffield Teaching Hospitals NHS Foundation Trust and any of its employees will not be responsible for any misuse of samples issued in this programme.

COSHH (Control of Substances Hazardous to Health): Specimens utilised by this trial are human derived and judged as having a minimal likelihood that pathogens are present. They have been virologically tested and found negative for Hepatitis B, Hepatitis C, Hepatitis E, HIV-1, HIV-2, HTLV1 and Syphilis, No material is knowingly used that is positive for pathogens. However, it should be handled in accordance with local laboratory Health & Safety practices.

Packaging: UK NEQAS LI sample(s) are sent by first class post or courier accordingly. Packaging is guided by Package Instruction P650.

Disposal/Spillage: The sample(s) cannot be assumed to be free from infectious agents therefore the material should be assessed as potentially infectious (refer to COSHH). In the event of a spillage during transportation the secondary packaging provided has sufficient absorbent capacity to absorb the enclosed peripheral blood sample(s). Damaged packaging and sample(s) should be disposed of in accordance with local Health & Safety and waste management practices. It is advised that any spillage should be dealt with in line with the local protocol for small volume blood spills. If no specific protocol is available, UK NEQAS LI suggests liberally covering the area with a suitable disinfectant (allowing sufficient contact time for effective action), absorbing the treated spillage with a paper towel before rinsing the area with water and drying thoroughly. See the section below for guidance on requesting a repeat sample.

REPEAT SAMPLES

Requests for repeat samples should be made by email (repeatsamples@ukneqasli.co.uk). Should this not be possible please telephone our Administration team on the number provided below. **Please make a repeat sample request as soon as possible. If following repeat sample(s) processing, results obtained still do not pass local internal QC please contact UK NEQAS LI.**

Post-Stem Cell Transplant Chimerism Monitoring

TRIAL NO: 242501 **Participant:** 10001 **ISSUED:** 9-May-24 **CLOSING:** 7-Jun-24

RESULTS SUBMISSION

Please state your results as an integer in percentage (%) Donor units.

The data entry webpage for this trial can be accessed online at the UK NEQAS LI website via the **Participant Hub** (www.ukneqasli.co.uk). Participants are required to log into this area of the website using their Lab number (also known as PRN, participant reference number), Identity and Password.

Please only submit results applicable to the scope of this EQA programme.

UK NEQAS LI website hosted results submission pages have been designed to facilitate local independent checking of trial results prior to final submission. Once data has been entered into the relevant fields a participant can chose to click the [Save] button to permit independent checking by a second operative before final submission to UK NEQAS LI. The date and time will appear in the corresponding field to indicate data has been successfully saved. Subsequent editing of the data fields is still possible at this stage. **The [Submit] button must be clicked for data to be locked (preventing further editing) and transferred to UK NEQAS LI.** The date and time will appear in the corresponding field to indicate the trial data has been successfully submitted. Additionally, the date of successful results submission will also appear in the 'completed' column of the relevant programme trial list. Please note, all data **saved** or submitted in the UK NEQAS data entry system will be downloaded and analysed at trial closure.

If you experience any problems submitting your trial results, please do contact us (see contact details section) for assistance. Participants can make changes to existing laboratory contact details, request a password reminder or add a new contact at any time via the Participant Hub. Alternatively, please email (admin@ukneqasli.co.uk) or telephone the number provided below for assistance.

If you wish to return more than one set of results, please contact UK NEQAS LI. **Failure to return your results will be recorded as a non-return and for an accredited programme impact upon your performance status.** If you have any queries with regards to online data entry, please do not hesitate to contact us. It is the responsibility of participants to ensure that their results have been received by UK NEQAS LI. Further information can be found in the associated trial issue email and on our website (www.ukneqasli.co.uk).

REPORT DISTRIBUTION

The trial report for this programme will be available online at the UK NEQAS LI website (www.ukneqasli.co.uk). Participants are required to log into the **Participant Hub** (using their web user details) to retrieve PDF report(s). Participants will be notified regarding the availability of an issued report by email. To ensure you receive such emails please check the contact details we hold for your laboratory are accurate and current at re-registration. Participants can make changes to existing laboratory contact details, request a password reminder or add a new contact at any time via the Participant Hub. Alternatively, please email (admin@ukneqasli.co.uk) or telephone the number provided below for assistance.

CONTACT DETAILS

UK NEQAS LI, Pegasus House, 4th Floor, 463A Glossop Road, Sheffield, S10 2QD, UK.
Tel: +44 (0) 114 267 3600; e-mail: admin@ukneqasli.co.uk
Please state PRN (participant reference number) on all correspondence.